Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.849 -0.141 (-7.10%)

Streaming Delayed Price Updated: 12:17 PM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Earnings Preview For Coherus BioSciences ↗

August 01, 2023

Via Benzinga

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

July 26, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

10 Analysts Have This to Say About Coherus BioSciences ↗

July 14, 2023

Via Benzinga

Health Care Company Coherus BioSciences Announces Merger With Surface Oncology ↗

June 16, 2023

Via Benzinga

Coherus BioSciences Announces New Employment Inducement Grants

July 21, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

July 20, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details ↗

July 19, 2023

Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers.

Via Benzinga

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

July 13, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Analyst Expectations for Coherus BioSciences's Future ↗

June 15, 2023

Via Benzinga

Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer' ↗

July 11, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he's surprised by the slow progress of Rambus Inc. (NASDAQ: RMBS).

Via Benzinga

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

July 03, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability ↗

June 20, 2023

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.

Via Benzinga

Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June ↗

June 16, 2023

U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P...

Via Benzinga

Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients ↗

June 06, 2023

Via Benzinga

Why Is AbbVie Stock Trading Down Today? ↗

June 01, 2023

AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 16, 2023

Via Benzinga

Stocks Headed For Strong Weekly Wins ↗

June 16, 2023

Stocks are struggling for direction midday, but all three major indexes are on track for strong weekly gains.

Via Talk Markets

Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 16, 2023

Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781.

Via Benzinga

Crude Oil Rises; Adobe Posts Upbeat Results ↗

June 16, 2023

U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,...

Via Benzinga

Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday ↗

June 16, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%...

Via Benzinga

US Stocks Mixed; Dow Gains 50 Points ↗

June 16, 2023

U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to...

Via Benzinga

This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? ↗

June 16, 2023

Via The Motley Fool

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M ↗

June 16, 2023

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that

Via Benzinga

Coherus to Acquire Surface Oncology

June 16, 2023

From Surface Oncology, Inc.

Via GlobeNewswire

AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry ↗

June 15, 2023

AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a...

Via Benzinga

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

June 05, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 ↗

June 02, 2023

Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics.

Via Talk Markets

Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗

June 01, 2023

One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...

Via Benzinga

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

June 01, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.